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anti-inflammatory melanin-like nanoparticles
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Here, a microfluidic approach for superfast melanin-like nanoparticle
preparation with tunable size and monodispersity is reported. The
particles formed have similar chemical composition to those prepared
by the bulk method, and show reactive oxygen species scavenging
behaviour and inflammatory macrophage phenotype switching cap-
ability, suggesting their potential for anti-inflammatory applications.
Cephalopods, including octopuses, cuttlefish and squids, are
well-known for their unique inking behavior when disturbed.
The dark-colored ink comprises melanin nanoparticles (MNs)
secreted from the ink sac, as well as chemicals and polymeric
contents from the funnel gland.1 Cephalopod ink has been
used in medicine since ancient times both in Western and
Eastern culture, without knowing the real active components.2
Recent studies found that MNs from Sepia ink had superior
antioxidant potency due to the reactive oxygen species (ROS)
scavenging capability.3–5 Considering the prevalent oxidative
stress closely associated with inflammation, especially chronic
non-resolving inflammation associated diseases,6,7 MNs from
cephalopod inkmay show promising potential in anti-inflammatory
applications.
The biosynthesis ofmelanin in cephalopods is a highly regulated
process confined in intracellular vesicles called melanosomes
(0.5–1 mm in diameter), where tyrosine and 3,4-dihydroxy-
L-phenylalanine (DOPA) substrates undergo a series of enzyme-
cascade reactions and finally form MNs.8 Unlike the ellipse-shaped
melanin microparticles produced by vertebrates, MNs produced by
cephalopods are uniform and spherical, with an average size of
approximately 150 nm.9 By transmission electronmicroscopy (TEM)
imaging, it was identified that one melanosome can accommodate
up to 30 MNs.10 Such concentrated MNs made in the melanosomes
are speculated to be synthesized from locally concentrated
substrates in a highly catalytic environment, somehow uniquely
developed in evolution.
Inspired by the efficient and well-controlled biosynthesis of
MNs, we developed a glass capillary-based microfluidic device
for producing monodisperse MNs from concentrated dopamine
with fine-tuning of the size and morphology (Fig. 1a). Although
some artificial MN preparation methods have been reported by
bottom-up self-polymerization in alkaline solutions,11–13 only
very dilute substrates were allowed at slow reaction rates (typically
1–3 day reaction time) to prepare homogenous MNs. At a higher
substrate concentration, the reaction becomes too fast, leading to
uncontrollable nanoparticle (NP) formation with heterogeneous
properties. In contrast, microfluidic technology enables precise
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We propose a new concept utilizing the microfluidic technique for superfast,
controllable and monodisperse melanin nanoparticle (MN) production,
inspired by MN biosynthesis from cephalopods. With high biocompatibility,
biodegradability and free radical scavenging abilities, melanin has been
intensively used as an antioxidant, photothermal agent and surface coating
material in the biomedical field. Although traditional MN preparation
methods generate homogenous nanoparticles, the lengthy reaction times
and unavoidable batch-to-batch variations limit the possibility to tailor
particle production towards real-world applications. Thanks to the
microfluidic technique, here we demonstrate that monodisperse MNs can
be produced in a highly concentrated substrate solution within seconds for
the first time. By simply adjusting the parameters of the microfluidic device,
we can precisely manipulate the size and the morphology of the produced
nanoparticles. These MNs made with the microfluidic method showed
similar chemical composition to those prepared by the bulk method. The
negligible toxicity towards macrophages, reactive oxygen species scavenging
capability, and inflammation attenuating effects towards M1 phenotype
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control of superfast liquid mixing and mass transfer in complex,
miniaturized capillary networks.14–20 Within milliseconds, all the
reagents efficiently mix, resulting in a homogenous environment
throughout.21–23
As shown in Fig. 1a, the co-flow microfluidic device for MN
production is composed of three sequentially aligned glass
capillaries. Dopamine hydrochloride was dissolved in Milli-Q
water as the inner fluid and pumped into the inner tapered
glass capillary, while concentrated sodium hydroxide (NaOH)
solution, as the 1st outer fluid, was pumped between the inner
and 1st outer cylindrical capillary. Once mixed with NaOH,
dopamine started self-polymerization followed by oligomer
aggregation to formMNs. Then, the 2nd outer fluid, concentrated
hydrochloric acid (HCl), was pumped into the space between the
1st and the 2nd outer cylindrical capillaries. When the MNs in
the 1st outer fluid encountered the HCl, the self-polymerization
of dopamine, which is pH-dependent, was terminated due to the
acidification of the solutions. Thus, by controlling the distance
(marked as D in Fig. 1a) between the tip of the tapered capillary
and the end of the 1st outer cylindrical capillary, the reaction
time of dopamine polymerization was precisely controlled, which
in turn tuned the size and morphology of the MNs. The variation
of D shows the time resolution of MN particle formation by
spatial resolution within the microfluidic chip, which provides
unique insight into the reaction kinetics.
The size and morphology of the MNs produced by the
microfluidic device with different D values (3 cm, 4.5 cm and
12 cm) were characterized by dynamic light scattering (DLS)
and TEM. As shown in Fig. 1b–d, when D increased from 3 to
12 cm, the size of the MNs increased and the particles became
Fig. 1 (a) The schematic illustration of MN preparation on a co-flow glass-capillary microfluidic device in parallel with a cuttlefish inking comparison.
(b–d) TEM images of the MNs prepared by the microfluidic device with different parameters (D = 3, 4.5 and 12 cm, respectively). Scale bar = 500 nm in the
main image and 100 nm in the inset. (e–g) DLS size distribution profiles of the MNs prepared by the microfluidic device with different parameters
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denser with higher contrast in TEM images. The DLS results
also confirm the trend, because the whole distribution profile
shifted to larger sizes with an increase in D (Fig. 1e–g). Within
5.08 s (D = 3 cm), loosely assembled NPs with slightly irregular
shape (Fig. 1b and inset) were already formed. The rough
surface was possibly due to the random aggregation in such a
short time. The particle size shown in TEM was smaller than
that measured by DLS (Fig. 1e), suggesting that the NPs were
possibly quite swollen and hydrated.13 After another 2.54 s
(D = 4.5 cm), the hydrodynamic size of the NPs increased by
31 nm, with a smaller PDI. Notably, the MNs became rounder,
solid and smooth (Fig. 1c and inset), indicating that the particle
growth homogenized the particle surface, and the size distribution
became narrower. On elongating the reaction time to 20.32 s
(D = 12 cm), the hydrodynamic size of the MNs increased to
381 nm, but still with monodispersity (Fig. 1d and g). At this stage,
the aggregation became more evident, and more merged particles
could be identified in the TEM image. The overall results shown
above suggest that monodisperse MNs of controllable sizes can be
easily prepared within a few seconds by this novel microfluidic
device, using 100 times more concentrated dopamine substrate
(200 mg mL1 dopamine) compared with the conventional bulk
method.13
In comparison, we also used the same condition to produce
MNs by the conventional bulk method. After rapidly mixing
dopamine and NaOH solutions, HCl was immediately added to
terminate the reaction. However, the MNs synthesized were
polydisperse with micro-size aggregates (Fig. 2a and b). This
was possibly because the reaction and subsequent particle
formation were faster than the mixing. Therefore, the spatial
and temporal heterogeneities led to uncontrollable particle
formation and aggregation. A further increase of the reaction
time to 20 h did not make the particles small or homogenous
(Fig. S1, ESI†), suggesting that the aggregation right after the
NaOH addition was irreversible.
Then, we decreased the dopamine concentration to 1.5mgmL1,
close to the concentration range reported in conventional bulk MN
synthesis methods.13 As shown in Fig. 2c, MN formation was
significantly slower at such a low concentration of dopamine.
Although the colour of the reaction solution changed to dark
yellow immediately after the reaction was initiated (Fig. S2,
ESI†), the count rate in the first 5 min remained almost the
same, without any identifiable particles (Fig. S3, ESI†). After 5 min,
the count rate started to increase, indicating the formation of
nanoparticles with light-scattering capabilities. During the first
1 h, the Z-average size of the particles remained almost the same,
with the PDI greatly decreased. At the same time, the count rate
increased. Since the count rate is proportional to c r6 (c represents
the particle concentration and r represents the particle size),24 this
means that the number of MNs in the solution increased during the
first hour, probably due to the particle nucleation. The supersatura-
tion of soluble oligomers caused MNs of around 30 nm to nucleate
continuously during this initial stage. Afterwards, the particle size
grew steadily with time, with a slightly increased PDI, suggesting
slow particle growth. After 24 h, the particles reached a size of
65.3 nm with a PDI of 0.16 (Fig. S4, ESI†). A further increase in
the reaction time led to larger aggregates (104.2 nm at 48 h and
262.3 nm at 72 h) with larger size distribution.
Given the above results, we made a comparison of the MN
formation kinetics with the bulk method using diluted dopamine
Fig. 2 (a and b) DLS distribution profile and TEM image of the MNs prepared by the bulk method at 200 mg mL1 dopamine. Scale bar = 500 nm. (c) The
Z-average size and PDI of MNs prepared by the bulk method at 1.5 mg mL1 dopamine. (d) The schematic showing MN formation kinetic steps in the
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and with the microfluidic method using concentrated dopamine.
According to the literature, the generally accepted simplified MN
formation mechanism involves 4 steps, including dopamine
oxidation, oligomer formation, oligomer aggregation, and aggre-
gate growth (Fig. 2d).25 First, dopamine was auto-oxidized by the
dissolved oxygen in the alkaline solution to form quinone, and
further converted to 5,6-dihydroxyindole (DHI) and indole-5,6-
quinone (IDQ).26 Further oxidation of DHI and IDQ leads to the
formation of oligomers (1.0–1.5 nm), which quickly aggregate
and form ‘‘seeds’’.27 The polymer grows steadily from these
‘‘seeds’’ by continuous addition of monomers or dimers by
covalent or non-covalent bonding during the polymerization
process,28,29 finally generating nano- or micro-sized particles.
At a low concentration of dopamine, the oxidation and oligomer
formation were slow (45 min). This allows for thorough mixing of
all reactants in the solution before reaching the supersaturation of
MN precursors. Therefore, the nucleation proceeded in a relatively
homogenous environment, and the subsequent growth in such a
dilute solution was possibly diffusion-controlled, resulting in mono-
disperse particles after hours or days. In the microfluidic system,
all the steps were superfast, due to the high concentration of
dopamine. Themixing was also fast and highly efficient, leading to
a similarly homogenous environment for nanoparticle nucleation.
Therefore, monodisperse particles, with precisely controlled
initiation of self-polymerization of dopamine, aggregation of
oligomers and termination of the reaction, can be produced in a
microfluidic device within a few seconds.
As the MN formation kinetics on microfluidic chips differed
from that of conventional bulk methods, we hypothesized that
the structure and physiochemical properties were affected by
the preparation methods. We first compared the size and
morphology of the synthetic MNs with natural MNs from Sepia,
which is considered as a standard of eumelanin.30 The Sepia
MNs acquired from a commercial supplier after reconstitution
in water showed a broad distribution profile with more than
one peak (Fig. S5, ESI†). Even after the removal of aggregates
using low speed centrifugation, there were still some micro-
sized particles, as shown in the DLS size distribution profile
(Fig. 3a). The morphology of these particles was compact and
spherical (Fig. 3b), consistent with previous literature.13 The
zeta-potential of all MNs was similar (around 30 mV) (Table
S1, ESI†). Further stability studies at 37 1C in 50% human
plasma showed no obvious size change over a 2 h incubation
period (Fig. S6, ESI†). The PDI of the MNs in plasma was higher
than that in water, probably due to the high protein content in
the plasma, which caused a bimodal distribution.31,32
The chemical composition of MNs prepared by the micro-
fluidic technique, prepared by the bulk method (slow reaction)
and natural MNs from Sepia was examined by Fourier-transform
infrared spectroscopy (FTIR). As shown in Fig. 3c, the MNs from
Sepia had broad bands around 3380, 1590 and 1354 cm1,
corresponding to N–H stretching from secondary amine, CQC
aromatic ring stretching and C–N–C stretching from indole
rings.33 The broad bands clearly differed from those sharp
and split bands shown in the dopamine FTIR spectrum, indicating
the heterogeneous polymeric nature of the MNs. The frequencies
and the band shape are in good agreement with published
frequencies of similar samples.33,34
Fig. 3 (a and b) DLS distribution profile and TEM image of the MNs from Sepia after low speed centrifugation. Scale bar = 500 nm. (c) The FTIR spectra of
MNs from Sepia (black), MNs synthesized by the bulk method (red), MNs synthesized by the microfluidic method (blue) and dopamine (grey). (d) The
UV-vis absorbance spectra of MNs from Sepia (black), MNs synthesized by the bulk method (red), MNs synthesized by the microfluidic method (blue) and
dopamine (grey dash line). (e) The H2O2 scavenging capability of MNs at different concentrations (10, 20 and 50 mg mL
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The synthetic MNs showed identical FTIR spectra, regard-
less of the preparation method (Fig. 3c). Notably, the synthetic
MNs’ spectra showed several different bands between 1800 and
900 cm1 compared with the natural MNs. First, there is an
additional band at 1715 cm1, corresponding to CQO stretch-
ing (zoomed in FTIR spectra in Fig. S7, ESI†). This carbonyl
group may originate from the ketonic carbonyl of quinone
groups, or from the carboxylic acids on dihydroxyindole-2-
carboxylic acid (DHICA) and other derivatives.35 Other differences
include a series of bands emerging at 1610, 1510 and 1436 cm1,
compared with one broad and smooth band in the natural MNs’
spectrum. The multiple bands are all correlated to the CQC
aromatic ring stretching in different chemical environments,
suggesting a heterogeneous structure. The strong bands at 1280
and 1224 cm1 corresponding to the C–O vibration might
originate from the hydroxyl groups from DHI.33,34 These differences
in the FTIR spectra suggest that the chemical composition of
synthetic MNs from the bulk and microfluidic methods is
similar, but differs from the natural MNs.
The UV absorbance spectra of all MNs (Fig. 3d) showed
typical broad absorbance from UV to near infra-red wavelengths,
due to the chemical and structural disorder.36,37 The shapes of the
absorbance spectra of MNs prepared by the microfluidic and MNs
prepared by the bulk method are identical, with a small peak at
280 nm, suggesting residual dopamine or other low molecular
weight precursors absorbed on the nanoparticles. MNs from Sepia
had a smoother absorbance profile without any obvious peak, and
the absorbance is slightly higher than that of the synthetic MNs
in the infra-red region, which suggests that there might be some
differences in the hierarchical assembly structure within the
particles.38
Next, we evaluated the ROS scavenging capability of MNs
synthesized by the microfluidic method. We first evaluated whether
the MNs can scavenge hydrogen peroxide (H2O2), which is a main
type of cellular ROS.7,39 MNs were incubated with H2O2 (10 mM,
which is detrimental to cells and leads to necrosis40,41) for 1 h and
the remaining H2O2 concentration was evaluated by Amplext Ultra-
Red reagent. As shown in Fig. 3e, the H2O2 scavenging capability of
the MNs is concentration-dependent. At 20 mg mL1, the MNs
decreased the H2O2 concentration by half, and further decreased
it to 25% at a concentration of 50 mg mL1. The H2O2 scavenging
activity might be attributed to the DHICAmoieties in the MNs, as
shown in the FTIR spectrum.
Surprisingly, the Sepia MNs did not show H2O2 scavenging
capability in the studied concentration range (Fig. 3e). It has
long been known that Sepia MNs react with H2O2,
42 and a high
concentration of H2O2 bleaches natural MNs generated by
various species.43 However, most previous studies regarding
Sepia MNs used fresh MNs purified from Sepia ink, instead of
lyophilized samples from a commercial supplier. There is
evidence showing that the purification method affected the
composition of the final MNs,44 as well as the morphology.9 It is
likely that the commercial MNs, after purification, lyophilization
and rehydration, lost the H2O2 scavenging capability.
Based on the H2O2 scavenging capability of the MNs pre-
pared by the microfluidic technique, we decided to investigate
the antioxidant and anti-inflammatory potential of the material
in biological systems. As a proof-of-concept study, we decided
to evaluate the MNs on macrophage cells, which are key players
in inflammation development. Pro-inflammatory macrophages
(M1 phenotype) secrete high levels of pro-inflammatory cytokines
such as tumor necrosis factor-alpha (TNF-a), interleukin (IL)-1b,
IL-12 and IL-23, and contribute to inflammation progression.45–47
In contrast, the M2 phenotype secretes anti-inflammatory
cytokines (e.g., IL-10 and transforming growth factor-beta)
and promotes tissue repair.48–50 Therefore, switching the M1
to the M2 phenotype using anti-inflammatory nanoparticles is a
promising strategy for anti-inflammatory therapy.51
Before the evaluation of the anti-inflammatory potency, we
first tested the cytotoxicity of the MNs on RAW 264.7 cells,
which are typical murine macrophages. The cells were cultured
with MNs for 6, 24 and 48 h, respectively, and the cell viability
was assessed by the CellTiter-Glos luminescence assay. As shown
in Fig. 4a, the MNs had negligible cytotoxicity at concentrations
lower than 100 mg mL1. When the concentration increased to
500 mg mL1, the cell viability was 75% at 6 h, 68% at 24 h and
Fig. 4 (a and b) The cytotoxicity of MNs prepared by the microfluidic method on RAW 264.7 cells (a) and THP-1 cells (b) after 6, 24 and 48 h incubation.
The results were normalized to the untreated controls. Data are presented as the mean  s.d. (n = 4). *Po 0.05, **Po 0.01, and ***Po 0.001. (c and d)
The confocal images showing the ROS level in RAW 264.7 cells stimulated by LPS and IFN-g for 24 h, and then treated without particles (c) and with MNs
at 20 mg mL1 (d). The intracellular ROS level was indicated by the green fluorescence emitted by dichlorofluorescein. The plasma membranes were
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65% at 48 h. The increased cytotoxicity was probably due to the
cellular uptake of MNs, which was confirmed by flow cytometry and
confocal microscopy (Fig. S8, ESI†). We further tested the cytotoxi-
city on THP-1 cells (human monocytes, which are commonly used
for macrophage differentiation). The results were similar to those of
RAW 264.7 (Fig. 4b), which showed decreased cell viability when the
concentration was higher than 100 mg mL1.
The ROS scavenging capability of the MNs was evaluated on
inflamed RAW 264.7 cells. Prior to the NP incubation, RAW
264.7 cells were stimulated by lipopolysaccharides (LPS) and
interferon-gamma (IFN-g), which are common reagents for
inducing oxidative stress and inflammatory responses.46 Then
the cells were treated with MNs for 5 h, before analyzing using the
oxidant-sensing fluorescent probe 20,70-dichlorodihydrofluorescein
diacetate (DCFH-DA). Non-polar DCFH-DA can diffuse through cell
membranes into the cytoplasmwhere it gets hydrolyzed by esterases
and subsequently oxidized by ROS to become fluorescent.52 The
fluorescence intensity of all cells was then analyzed by confocal
microscopy. As shown in Fig. 4c and d, the prevalent green
fluorescence emitted by oxidised DCFH in the positive control (cells
stimulated by LPS and IFN-g) confirmed the high ROS level. Cells
treated with MNs showed slightly decreased green fluorescence
compared with the positive control, although some cells were not
fully recovered, possibly due to the short incubation time.
Further characterization of the ROS scavenging capability
was performed on RAW 264.7 cells challenged by concentrated
H2O2. Quantitative analysis using DCFH-DA suggested that the
cells treated with MNs showed a lower ROS level compared with
the positive control, and a higher concentration of MNs led to
better scavenging effects (Fig. S9, ESI†). At 50 mg mL1 of MNs,
the ROS level became 10% lower after 45 min challenge, and
20% lower when the challenge time was elongated to 90 min.
We also used a small molecule ROS scavenger, L-glutathione
(GSH), as a control. The preloaded GSH caused a 14% decrease
in ROS at 45 min, but almost no effects at 90 min, probably due
to the fast metabolism.53
Next, we evaluated the anti-inflammatory therapeutic efficacy
on RAW 264.7 macrophages. As shown in Fig. 5a, the macro-
phages in the resting state (M0) were first stimulated by LPS and
IFN-g for 1 day, and then treated with MNs. The cells stimulated
by LPS and IFN-g but without any treatment developed into the
M1 phenotype (M1 control), while those M0 cells with anti-
inflammatory cytokine stimulation (IL-4 and IL-13) for 3 con-
secutive days developed into the M2 phenotype (M2 control).
The M1 and M2 phenotypes have distinguishable markers on
the surface and cytokine secretion profiles.46 Therefore, we
evaluated the expression of CD80 (M1 marker) and CD206 (M2
marker) by immunostaining and subsequent analysis by flow
cytometry, as well as the concentration of TNF-a (M1 cytokines)
and IL-10 (M2 cytokines) by enzyme-linked immunosorbent
assay (ELISA), to identify the phenotypes after treatment.
As shown in Fig. 5b and c, MNs reduced the pro-inflammatory
cytokine TNF-a effectively to almost the M0 level. At the same time,
the anti-inflammatory cytokine IL-10 secretion was elevated,
suggesting potent inflammation-attenuating effects. Further
investigation on the cell marker by flow cytometry showed that
the M1 typical marker CD80 of MN treated cells decreased
significantly compared with the M1 control (Fig. 5d). The M1
phenotype population (CD80+ CD206) decreased from 92.2%
to 27.3%, with an increase of 10% in the M2 phenotype (CD80
CD206+) population. Around half of the cells (52.1%) became
double negative, suggesting the transformation into a resting
Fig. 5 (a) Schematic representation of the macrophage stimulation and treatment. (b and c) The concentration of TNF-a and IL-10 in the macrophage
culture medium after stimulation and treatment, quantified by ELISA. Data are presented as the mean  s.d. (n = 3). (d) The flow cytometry analysis of
macrophage marker CD80 and CD206 expression after immunostaining. Control (ctrl) represents cells without LPS and IFN-g stimulation. MN represents
cells stimulated by LPS and IFN-g and treated with MNs at 20 mg mL1 for 2 days. LPS&IFN represents the M1 control with continuous pro-inflammatory
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M0 state. This means that the inflammation attenuation effect
of the MNs was due to the macrophage phenotype conversion. The
molecular mechanism behind the phenotype conversion by MNs is
possibly related to the down-regulation of Toll-like receptor 4
expression (for sensing LPS) and NF-kB signaling pathway.54
Conclusions
In this study, we developed melanin-like nanoparticles by
superfast and controlled preparation in microfluidic devices
inspired by cephalopods. The MNs were generated from highly
concentrated substrates within seconds, which is comparable
to the biosynthesis. Characterized by DLS and TEM, the particles
showed spherical morphology and monodisperse size, due to the
superfast mixing and the precise control of initiation and
termination of the reaction. Furthermore, the MNs prepared by
the microfluidic method successfully reduced the pro-inflammatory
cytokine level and induced the secretion of immune-suppressive
cytokines IL-10 on macrophages, and altered the cell phenotype.
The simple but advanced preparation of MNs by a microfluidic
device, along with the inflammation attenuating property, makes
the nanoparticles developed here a promising candidate for anti-
inflammatory applications.
Experimental
Details of the experimental procedures are provided in the ESI.†
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